Phosphoric Acid — predicted protein targets

Known targets — ChEMBL curated mechanism

ADRA1A ADRA1B ADRA1D ADRB1 ADRB2 ADRB3 CYP11B1 DPP4 FGFR1 FGFR2 FGFR3 FGFR4 HRH1 JAK1 JAK2 JAK3 KCNA1 KCNA10 KCNA2 KCNA3 KCNA4 KCNA5 KCNA6 KCNA7 KCNB1 KCNB2 KCNC1 KCNC2 KCNC3 KCNC4 KCND1 KCND2 KCND3 KCNF1 KCNG1 KCNG2 KCNG3 KCNG4 KCNH1 KCNH2 KCNH3 KCNH4 KCNH5 KCNH6 KCNH7 KCNH8 KCNQ1 KCNQ2 KCNQ3 KCNQ4 KCNQ5 KCNS1 KCNS2 KCNS3 KCNV1 KCNV2 KDR KIT NA OPRD1 OPRK1 OPRM1 P PDGFRB PIK3CD SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SMO TYK2 pol rplA rplB rplC rplD rplE rplF rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmF rpmG rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	JAK2 known ✓	O60674	15/20	0.77

▸	JAK1 known ✓	P23458	12/20	0.77

▸	JAK3 known ✓	P52333	7/20	0.77

▸	TYK2 known ✓	P29597	4/20	0.77

▸	FGFR1 known ✓	P11362	2/20	0.68

▸	KIT known ✓	P10721	1/20	0.68

▸	KDR known ✓	P35968	1/20	0.48

▸	HDAC6	Q9UBN7	3/20	0.68

▸	DAPK3	O43293	2/20	0.68

▸	PAK4	O96013	2/20	0.68

▸	ABL1	P00519	2/20	0.68

▸	RET	P07949	2/20	0.68

▸	LTK	P29376	2/20	0.68

▸	CSNK1A1	P48729	2/20	0.68

▸	CLK2	P49760	2/20	0.68

▸	TNK2	Q07912	2/20	0.68

▸	ROCK1	Q13464	2/20	0.68

▸	DYRK1A	Q13627	2/20	0.68

▸	IKBKE	Q14164	2/20	0.68

▸	NTRK3	Q16288	2/20	0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL16218910	0.91	JAK2 (0.77)	JAK2JAK1JAK3TYK2HDAC6
SCHEMBL100309	0.91	JAK2 (0.77)	JAK2JAK1JAK3TYK2HDAC6
Ruxolitinib SCHEMBL1371422	0.87	JAK2 (1.00)	JAK2JAK1JAK3TYK2HDAC6
Ruxolitinib SCHEMBL29677819	0.87	JAK2 (1.00)	JAK2JAK1JAK3TYK2HDAC6
Ruxolitinib SCHEMBL31073616	0.87	JAK2 (1.00)	JAK2JAK1JAK3TYK2HDAC6
Ruxolitinib SCHEMBL29357426	0.87	JAK2 (1.00)	JAK2JAK1JAK3TYK2HDAC6
Ruxolitinib SCHEMBL1369365	0.87	JAK2 (1.00)	JAK2JAK1JAK3TYK2HDAC6
Trifluoroacetic Acid SCHEMBL101747	0.86	JAK2 (0.65)	JAK2JAK1JAK3TYK2HDAC6
SCHEMBL24505546	0.85	JAK2 (0.74)	JAK2JAK1JAK3TYK2HDAC6
SCHEMBL101864	0.84	JAK2 (0.74)	JAK2JAK1JAK3TYK2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20240041887-A1	COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR	INCYTE CORP (US)	2024-02-08	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20240041887-A1	COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR	ALK, JAK2, ABL2	JAK2 2/4885JAK1 5/4885JAK3 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.